Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.47 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 5/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565911 | 0.93 | MOGAT2 (0.45) | S1PR1MOGAT2PLK1PLK3KAT8 | |
| SCHEMBL566155 | 0.89 | MOGAT2 (0.40) | S1PR1MOGAT2PLK1PLK3KAT8 | |
| SCHEMBL566444 | 0.87 | S1PR1 (0.45) | S1PR1MOGAT2PPARAS1PR3S1PR4 | |
| SCHEMBL575036 | 0.82 | S1PR1 (0.49) | S1PR1MOGAT2PLK1PLK3KAT8 | |
| SCHEMBL566312 | 0.81 | S1PR1 (0.40) | S1PR1PLK1PLK3KAT8PPARA | |
| SCHEMBL566293 | 0.81 | S1PR1 (0.43) | S1PR1PLK1PLK3SPHK1 | |
| SCHEMBL564904 | 0.79 | S1PR1 (0.46) | S1PR1PLK1 | |
| SCHEMBL177319 | 0.77 | SPHK1 (0.43) | S1PR1PLK1PLK3S1PR3S1PR4 | |
| SCHEMBL565825 | 0.75 | S1PR1 (0.49) | S1PR1PLK1PLK3S1PR3S1PR4 | |
| SCHEMBL566060 | 0.70 | PRKCG (0.35) | KAT8PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885MOGAT2 1672/4885PLK1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.